<DOC>
	<DOC>NCT01821846</DOC>
	<brief_summary>This trial is conducted in Asia. The aim of this study is to investigate the safety profile of liraglutide (Victoza®) under normal conditions of use in Korean subjects with type 2 diabetes mellitus.</brief_summary>
	<brief_title>Investigating the Safety Profile of Liraglutide Under Normal Conditions of Use in Korean Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Subjects with T2DM (Type 2 Diabetes Mellitus), including newlydiagnosed subjects, who require treatment with Victoza® according to the clinical judgment of their treating physician Subjects (and/or parents or the subject's legally acceptable representative) who are capable of giving studyspecific signed informed consent before any collection of information Subjects with a hypersensitivity to Victoza® or to any of the excipients Subjects who are pregnant, breast feeding or have the intention of becoming pregnant within the study periods Subjects with personal or family history of medullary thyroid carcinoma (MTC) Subjects with multiple endocrine neoplasia syndrome type 2 (MEN2)</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>